LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ)
CNY 7.25
(-0.82%)
CNY 7.25
(-0.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 135.36 Million CNY | -24.66% |
| 2022 | 190.35 Million CNY | 39.43% |
| 2021 | 161.95 Million CNY | 40.22% |
| 2020 | 58.41 Million CNY | -26.98% |
| 2019 | 141.09 Million CNY | 14.57% |
| 2018 | 123.24 Million CNY | 10.15% |
| 2017 | 110.03 Million CNY | 24.42% |
| 2016 | 89.36 Million CNY | 34.64% |
| 2015 | 68.24 Million CNY | 17.6% |
| 2014 | 37 Million CNY | -4.04% |
| 2013 | 56.81 Million CNY | 8.48% |
| 2012 | 60.44 Million CNY | 13.61% |
| 2011 | 51.19 Million CNY | -33.95% |
| 2010 | 70.54 Million CNY | 25.54% |
| 2009 | 43.16 Million CNY | 27.94% |
| 2008 | 43.83 Million CNY | 21.17% |
| 2007 | 37.36 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 28.16 Million CNY | -30.94% |
| 2024 Q3 | 4.43 Million CNY | -84.24% |
| 2024 Q1 | 41.15 Million CNY | 44.89% |
| 2023 Q4 | 36.87 Million CNY | 986.72% |
| 2023 FY | - CNY | -24.66% |
| 2023 Q3 | -4.15 Million CNY | -110.71% |
| 2023 Q1 | 27.89 Million CNY | -69.39% |
| 2023 Q2 | 38.8 Million CNY | 39.11% |
| 2022 Q4 | 91.13 Million CNY | 4121.02% |
| 2022 Q3 | 2.15 Million CNY | -91.83% |
| 2022 FY | - CNY | 39.43% |
| 2022 Q2 | 26.42 Million CNY | -18.33% |
| 2022 Q1 | 32.35 Million CNY | 43.82% |
| 2021 Q2 | 29.6 Million CNY | 20.15% |
| 2021 Q4 | 22.5 Million CNY | 25.26% |
| 2021 FY | - CNY | 40.22% |
| 2021 Q1 | 24.64 Million CNY | 309.9% |
| 2021 Q3 | 17.96 Million CNY | -39.33% |
| 2020 Q3 | 12.72 Million CNY | -57.7% |
| 2020 Q1 | 15.59 Million CNY | 1230.65% |
| 2020 FY | - CNY | -26.98% |
| 2020 Q4 | 6.01 Million CNY | -52.78% |
| 2020 Q2 | 30.09 Million CNY | 92.91% |
| 2019 Q2 | 43.89 Million CNY | 270.77% |
| 2019 Q4 | -1.37 Million CNY | -104.09% |
| 2019 FY | - CNY | 14.57% |
| 2019 Q1 | 11.83 Million CNY | -68.27% |
| 2019 Q3 | 33.77 Million CNY | -23.07% |
| 2018 Q2 | 19.02 Million CNY | 1.53% |
| 2018 FY | - CNY | 10.15% |
| 2018 Q4 | 37.31 Million CNY | 224.78% |
| 2018 Q3 | 11.49 Million CNY | -39.62% |
| 2018 Q1 | 18.74 Million CNY | -62.78% |
| 2017 FY | - CNY | 24.42% |
| 2017 Q3 | 12.39 Million CNY | -19.39% |
| 2017 Q4 | 50.35 Million CNY | 306.14% |
| 2017 Q2 | 15.37 Million CNY | 34.42% |
| 2017 Q1 | 11.44 Million CNY | -68.85% |
| 2016 Q4 | 36.73 Million CNY | 253.46% |
| 2016 Q1 | 7.25 Million CNY | -70.96% |
| 2016 Q2 | 28.6 Million CNY | 294.29% |
| 2016 FY | - CNY | 34.64% |
| 2016 Q3 | 10.39 Million CNY | -63.67% |
| 2015 Q4 | 24.98 Million CNY | 183.32% |
| 2015 Q3 | 8.81 Million CNY | -52.08% |
| 2015 Q2 | 18.39 Million CNY | 330.86% |
| 2015 Q1 | 4.27 Million CNY | -81.88% |
| 2015 FY | - CNY | 17.6% |
| 2014 Q4 | 23.56 Million CNY | 103.39% |
| 2014 Q3 | 11.58 Million CNY | -41.73% |
| 2014 Q2 | 19.88 Million CNY | 721.56% |
| 2014 Q1 | 2.42 Million CNY | -78.29% |
| 2014 FY | - CNY | -4.04% |
| 2013 Q3 | 13.04 Million CNY | -0.48% |
| 2013 Q1 | 4.96 Million CNY | -70.2% |
| 2013 Q4 | 11.14 Million CNY | -14.56% |
| 2013 FY | - CNY | 8.48% |
| 2013 Q2 | 13.1 Million CNY | 163.87% |
| 2012 Q1 | 5.91 Million CNY | -47.96% |
| 2012 Q2 | 8.85 Million CNY | 49.68% |
| 2012 Q3 | 8.02 Million CNY | -9.32% |
| 2012 FY | - CNY | 13.61% |
| 2012 Q4 | 16.67 Million CNY | 107.74% |
| 2011 FY | - CNY | -33.95% |
| 2011 Q4 | 11.36 Million CNY | -13.96% |
| 2011 Q3 | 13.2 Million CNY | 13.31% |
| 2011 Q2 | 11.65 Million CNY | 77.96% |
| 2011 Q1 | 6.54 Million CNY | -79.85% |
| 2010 Q3 | 11.09 Million CNY | 0.0% |
| 2010 Q4 | 32.5 Million CNY | 192.89% |
| 2010 FY | - CNY | 25.54% |
| 2009 FY | - CNY | 27.94% |
| 2008 FY | - CNY | 21.17% |
| 2007 FY | - CNY | 0.0% |